Steering Committee for FDA Policy on Veterinary Oversight of Antimicrobials


The AVMA Steering Committee for FDA Policy on Veterinary Oversight of Antimicrobials is expected to:

  • Ascertain the Food and Drug Administration's (FDA) expectations of the veterinary community and limitations in terms of regulatory and statutory authority as the Administration continues to establish policy on the role of veterinarians and veterinary use of antimicrobials.
  • Address the advisability and feasibility of various avenues of implementing greater veterinary oversight.
  • Be informed by relevant AVMA policies and, where necessary, provide scientific information and rationale.
  • Provide information to as well as solicit, consider, and thoroughly analyze feedback from relevant AVMA entities.
  • Advise on potential revisions to existing policy, as well as develop and recommend new policies as appropriate to the Board of Directors.

Membership, Method of Appointment, and Representation
The Steering Committee will comprise the following individuals:

Antimicrobial experts (5) – each with active AVMA membership; familiarity with practical aspects of field use of antimicrobials in food animal production; good interpersonal communication skills; knowledge of antimicrobial policy and regulation; balanced perspective and views of public health and animal agriculture. An advanced degree in public health, epidemiology, pharmacology, or microbiology is recommended.
The assembled team will be progressive thinkers, able to participate in critical strategic discussions, ask thought provoking questions, and challenge existing assumptions in order to identify and create a future vision for the framework of veterinary oversight of antimicrobials.

The Steering Committee and its chair will be appointed by the Board of Directorschair following solicitations from the general membership.

The Steering Committee is authorized to hold up to six meetings (two day, two night meetings) during the period 2011-2012.  Meetings may be at AVMA headquarters in Schaumburg, or in Washington DC as necessary in order to meet with FDA officials.

Travel expenses are authorized in accordance with the AVMA Travel Policy.

The Steering Committee will submit regular reports and updates to the relevant AVMA entities and the AVMA Board of Directors.  Recommendations from the Steering Committee will be submitted to the Board of Directors, following receipt, consideration, and detailed analysis of feedback from the relevant entities.

Life Expectancy
The Steering Committee will sunset at the end of 2012, unless it is continued by the Board of Directors.

November 4, 2010